ARTICLE | Clinical News
Fovista: Ph III OPH1003 data
December 16, 2016 8:24 PM UTC
The double-blind, sham-controlled, international Phase III OPH1003 trial in 626 patients with wet AMD showed that intravitreal injections of 1.5 mg Fovista plus 0.5 mg Lucentis ranibizumab missed the ...
BCIQ Target Profiles